
TSE:ZQQ
This summary was created by AI, based on 4 opinions in the last 12 months.
The BMO NASDAQ 100 Hedged to CAD Index ETF (ZQQ) has drawn mixed reviews from various experts regarding its suitability for investment. While it offers valuable exposure to technology stocks, concerns arise about the inherent volatility of these holdings, especially at the current market peak. One reviewer emphasizes the importance of adopting a disciplined investment strategy, suggesting that investors should be cautious given the historical fluctuations in tech stocks reminiscent of the dot-com bubble. There's a general skepticism towards hedged products like ZQQ, with some experts advocating for more direct investment strategies over relying on hedges that may not provide significant benefits in the long term. Additionally, reviews indicate that despite potential for growth, the current valuation of this ETF appears to be quite expensive, prompting recommendations for investors to consider diversifying their portfolios.
QQQ vs ZQQ? He thinks the Canadian dollar has over shot its real value here, so that factors into a Canadian hedged ETF. On an annual basis you should expect subdued growth for the next while. Having a decent weight in the NASDAQ makes sense.
ZQQ-T vs. TQQQ-N. The question is if you buy it with a currency hedge or the US version. If you are holding for the next few years, the Canadian dollar will be stronger down the road. He would prefer the ZQQ-T version but today is not the day to buy. In the next market decline he thinks some of the tech stocks will get hit.
He doesn't think there is anything wrong with tech, but everything that is good is already in the stock price. He would rather just pay Apple, Google and Microsoft.
[Is there an unhedged version or can he recommend a NASDAQ version] Larry recommends the QQQ-Q as there is no unhedged Canadian version.
Recognize this is not all technology. He doesn’t mind the NASDAQ index. It is hitting new highs and has names in the Tech space, but keep in mind that it does have names in the consumer discretionary space as well as the pharmaceutical biotech space. When you compare it against some of the other pure play technology ETF’s, it hasn’t done as well.